Young Americans' Marijuana Use Increases with Legalization: Survey

Nov.29.2022
Young Americans' Marijuana Use Increases with Legalization: Survey
Legalization of marijuana in the US has led to a significant increase in young adults smoking, according to a new survey.

A recent survey conducted in the United States has revealed a sharp increase in the number of young people consuming marijuana, following its legalization in many parts of the country, including New York.


A Gallup Poll analysis has revealed that 26% of individuals aged 18 to 29 have used marijuana, compared to 17% in 2015.


According to a Gallup report, smoking rates among young people have dropped from 35% in 2003 to 25% a decade ago, and now stand at 12%, which is more than two times lower than before.


According to an analysis by Gallup, smoking rates have dramatically declined in the past 20 years, driven mainly by a decrease in smoking among young people, which is encouraging for public health officials. However, more young people are turning to marijuana, possibly due to its legalization in more states and its prevalence among youth compared to traditional smoking, along with the use of e-cigarettes.


Twenty-one states have legalized the recreational use of marijuana, including several populous states on the East and West Coasts. Other states, such as Florida and Pennsylvania, have legalized marijuana for medicinal purposes.


According to Gallup's analysis, it supports a recent study published in the journal "Addictive Behaviors" by Temple University researchers. The study claims that "after the legalization of recreational marijuana use, the monthly usage rate among adolescents and young adults increased." The researchers warned that there will be an increase in marijuana addiction or untreated "marijuana use disorders.


The study also found that "among young adults, higher rates of marijuana use were associated with lower rates of hospitalization for CUD treatment.


Opponents of marijuana legalization say that their concerns are now in the past.


Due to coordinated preventative efforts, marijuana usage has steadily decreased for several decades. However, the legalization and commercialization of marijuana are now threatening to undo these public health benefits. "Smart Approaches to Marijuana" President Kevin Sabet stated, "We also cannot ignore the fact that young people are starting to use new forms of marijuana, such as e-cigarettes and concentrated products, which are closely linked to severe mental health risks and higher rates of addiction.


However, supporters say that they are pleased that people can use it legally.


I am delighted to be a part of this process. I am passionate about changing the stigma around cannabis. There is a certain stigma, but culture is changing," said Nicholas Koury, who last week received one of the first licenses issued by the state of New York to open a cannabis dispensary in Manhattan. "The stigma is not necessarily accurate. Cannabis can help people's mental state and has medicinal value," he said.


According to a survey, 26% of people aged 18 to 29 have admitted to using marijuana, which is higher than the reported 17% in 2015.


Last week, New York issued its first round of 28 cannabis dispensary licenses and is now tackling a rapidly growing unlicensed and unregulated black market where Budagges and other top shops openly sell marijuana and cannabis edibles.


According to a Gallup survey, some young smokers appear to be turning to e-cigarettes or less toxic electronic cigarettes, with approximately 7% of US adults reporting using them in the past week.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Swedish nicotine pouch brand Kelly White is building its strategy around adult female consumers. Founder and CEO Sophia Wilsby told 2Firsts that women accounted for around 70% of the brand’s repeat customers on HAYPP in Sweden in 2025. The interview explores female consumer segmentation, product and design differentiation, gender stereotypes, packaging regulation, and how independent brands can compete with global players such as ZYN and VELO while considering funding, partnerships and future ownership options.
Business
Sep.24
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
At InterTabac 2026, nicotine pouch growth was visible not only in brands but across equipment, raw materials and OEM manufacturing. 2Firsts interviewed AIRSCREAM commercial head Steve Moore on how many pouch factories Europe may ultimately need and where manufacturers can differentiate, from formulation and flavour to pouch materials, production consistency and customer service. The category continues to expand, but questions remain over future capacity, consolidation and the long-term structure of the supply chain.
Sep.18
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20